TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Biostem Technologies
BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers

BioStem Technologies announced successful clinical trial results for its BioRetain® allograft in treating diabetic foot ulcers, demonstrating a 53% healing probability compared to 31% with standard care.

Insights
BSEM   positive

Reported superior clinical trial results showing significant improvement in wound healing, highlighting potential commercial and medical value of their BioRetain® technology